The shift from volume to value in health care has presented life sciences companies with tremendous challenges and opportunities to proactively manage cost pressure and scientific innovation.
Truven Health Analytics®, an IBM Watson Health™ business, held discussions with more than a dozen life sciences companies to gather in-depth insights on their experience and intentions for outcomes-based contracts (OBCs). Viewed as an innovative way to improve patients’ access to the right therapies, life sciences companies are facing strategic and tactical challenges implementing OBCs.
In this brief, we share insights on the challenges in managing outcomes-based contracts (OBCs) with health plans today and solutions to address these challenges, based on our conversations with life sciences companies.
Over the years, the life sciences industry has been investing in capturing and analyzing patient health information. Specifically, companies have been creating digital health applications with the goal of improving treatment and care. ...read more
“We’re all patients,” noted Dr. Michelle McMurry-Heath, a panelist in the first plenary session that kicked off ISPOR 2018, a 5-day conference devoted to health economics and outcomes research (HEOR) in Baltimore at the end of May. ...read more